Stoke Therapeutics, Inc. reports results for the quarter ended September 30 - Earnings Summary

• Stoke Therapeutics, Inc. reported a quarterly adjusted loss of $1.08​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -65 cents. The mean expectation of fourteen analysts for the quarter was for a loss of 93 cents per share. Wall Street expected results to range from $-1.05 to -70 cents per share.

• Revenue rose 5.9% to $11.26 million from a year ago; analysts expected $8.18 million.

• Stoke Therapeutics, Inc.'s reported EPS for the quarter was a loss of $1.08​.

• The company reported a quarterly loss of $73.64 million.

• Stoke Therapeutics, Inc. shares had risen by 1.6% this quarter and lost 16.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 10.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Stoke Therapeutics, Inc. is $48.00, about 45.1% above its last closing price of $26.35

This summary was machine generated from LSEG data October 29 at 10:14 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)